Lead optimization of phthalazinone Phosphodiesterasas inhibitors as novel antitrypanosomal compounds.

Thumbnail Image
JMC 2020 final.pdf (1.42 MB)
Identifiers
URI: https://hdl.handle.net/10641/6214
ISSN: 0022-2623
DOI: 10.1021/acs.jmedchem.9b00985

Publication date

2020

Start date of the public exhibition period

End date of the public exhibition period

Authors

Advisors

Journal Title

Journal ISSN

Volume Title

Publisher

American Chemical Society
Metrics
Google Scholar
Share
Export

Research Projects

Organizational Units

Journal Issue

Abstract

Human African trypanosomiasis is causing thousands of deaths every year in the rural areas of Africa. In this manuscript we describe the optimization of a family of phtalazinone derivatives. Phosphodiesterases have emerged as attractive molecular targets for a novel treatment for a variety of neglected parasitic diseases. Compound 1 resulted to be a potent TbrPDEB1 inhibitor with interesting activity against T. brucei in a phenotypic screen. Derivative 1 was studied in an acute in vivo mouse disease model but unfortunately showed no efficacy. Its low metabolic stability is certainly one of the reasons. We report structural modifications to achieve compounds with an improved metabolic stability while maintaining high potency against TbrPDEB1 and T. brucei. Compound 14, presented a good microsomal stability in mouse and human microsomes and will be studied in the future in an acute in vivo T. brucei mouse model.

Doctoral program

Description

Keywords

Citation

Salado IG, Singh AK, Moreno-Cinos C, Sakaine G, Siderius M, Van der Veken P, Matheeussen A, van der Meer T, Sadek P, Gul S, Maes L, Sterk GJ, Leurs R, Brown D, Augustyns K. Lead Optimization of Phthalazinone Phosphodiesterase Inhibitors as Novel Antitrypanosomal Compounds. J Med Chem. 2020 Apr 9;63(7):3485-3507. doi: 10.1021/acs.jmedchem.9b00985

Collections

FACULTAD DE CIENCIAS EXPERIMENTALES